An implantable perfusion device (2) comprises a tubular transmission line (4) with an inlet end (6), an outlet end (8) and a flow restriction element (10) located therebetween, whereby an inlet section (12) of the transmission line is defined between the inlet end and the flow restriction element and whereby an outlet section (14) of the transmission line is defined between the flow restriction element and the outlet end. Moreover, the device comprises a perfusion chamber (16) containing a load of biologically active cells and is provided with a fluid entrance (18), a fluid exit (20) and a chamber volume (22) formed therebetween. The fluid entrance comprises at least one first microchannel platelet (24) and the fluid exit comprises at least one second microchannel platelet (26), each one of the microchannel platelets comprising at least one array of microchannels (28) defining a fluid passage between respective external and internal platelet faces, the microchannels having an opening of 0.2 to 10 μm. The fluid entrance (18) of the perfusion chamber is in fluid communication with the inlet section (12) of the transmission line; and the flow restriction element (10) is configured to establish a predetermined pressure excess in the inlet section (12) versus the outlet section (14).

An extracorporeal blood treatment module includes a plurality of gas transfer units, having a first polymer layer with a plurality of gas channels, a second polymer layer with a plurality of blood channels, and a gas permeable membrane disposed between the plurality of gas channels and the plurality of blood channels, a fluid transfer unit integrated with the plurality of gas transfer units, and including a third polymer layer having a plurality of fluid collection channels, a fourth polymer layer having a plurality of blood channels, and a fluid permeable membrane disposed between the plurality of fluid collection channels and the plurality of blood channels, and a housing containing the plurality of gas transfer units and fluid transfer unit.

A system, method or apparatus to detect abnormalities in delivery of a fluid may include an infusion apparatus that is controllable to cause one or more perturbations in a fluid flow (e.g., each of the one or more perturbations in the fluid flow may result in a measurable perturbed force response). A force signal representative of the perturbed force response may be used to determine an integrated perturbed force response value (e.g., using integration of the force signal over a perturbation time period; the integrated perturbed force response value being representative of an additional force caused by the at least one perturbation over an equilibrium force). A ratio between the integrated perturbed force response value and a normalizing value (e.g., based at least on a maximum perturbation force of the perturbed force response) may be used to determine if fluid flow is occluded.

The invention relates to a method of flushing an extracorporeal blood circuit, preferably an extracorporeal blood circuit of a dialysis machine, with a flushing liquid, wherein the flushing liquid contains an anticoagulant agent, preferably heparin. The invention further relates to an extracorporeal blood treatment unit, preferably to a dialysis machine, having an extracorporeal blood circuit and a control unit, wherein the control unit is configured to carry out a flushing method in accordance with one of the preceding claims before the start of the treatment and/or intermittently during the treatment.

The invention relates to extracorporeal blood circuits, and components thereof (e.g., hollow fiber membranes, potted bundles, and blood tubing), including 0.005% to 10% (w/w) surface modifying macromolecule. The extracorporeal blood circuits have an antithrombogenic surface and can be used in hemofiltration, hemodialysis, hemodiafiltration, hemoconcentration, blood oxygenation, and related uses.

The present disclosure provides, among other things, methods and systems for treating or removing blood clots in a biological fluid. In some embodiments, the present disclosure provides dialysis-like systems for capturing blood clots. The present disclosure encompasses the recognition that such methods and systems are useful for patients at risk for pulmonary embolism (e.g., patients with deep vein thrombosis and/or COVID-19 patients).

The disclosure relates to an alginate oligomer of 2 to 75 monomer residues, wherein said monomer residues do not carry a sulphate group, for use as a blood anticoagulant in clinical and non-clinical applications, including in vivo, ex vivo and in vitro contexts. The invention further provides for the use of such an alginate oligomer in preparing a product or device having a reduced capacity to promote blood coagulation, wherein said alginate oligomer is provided at or on a surface of said product or device. Such products and devices form a further aspect of the invention.

The invention relates to extracorporeal blood circuits, and components thereof (e.g., hollow fiber membranes, potted bundles, and blood tubing), including 0.005% to 10% (w/w) surface modifying macromolecule. The extracorporeal blood circuits have an antithrombogenic surface and can be used in hemofiltration, hemodialysis, hemodiafiltration, hemoconcentration, blood oxygenation, and related uses.

A cupping auxiliary consumable used in conjunction with one of the Chinese Medicine techniques, cupping. The characteristics include: a sanitary blood-absorbent pad suitable to insert into a cup during cupping treatment, and when applied, the layer against the human skin is made of a material that is permeable to blood. A cup kit for cupping is also provided, including: a cup and a sanitary blood-absorbent pad inserted into the cup. The cup can also include an adhesive surface connecting the cup and the skin; a releasing layer to protect the adhesive surface. The cupping operation can be carried out easily, the blood is absorbed into the blood-absorbent pad, thus will not soil the cup, keeping the entire cupping process hygienic.

Hollow fiber membranes in an oxygenator for an extracorporeal blood circulator are coated with an antithrombotic polymeric material. The porous hollow fiber membranes for gas exchange have outer surfaces, inner surfaces forming lumens, opening portions through which the outer surfaces communicate with the inner surfaces in a housing. A blood flow path is outside of the hollow fiber membrane bundle in the housing, between a blood inlet port and a blood outlet port. The coating is obtained by filling the blood flow path with a colloidal solution containing an antithrombotic polymeric compound, and moving the colloid solution between the blood inlet port and the blood outlet port for a time that coats a predetermined amount of antithrombotic polymeric compound on the outer surfaces of the hollow fiber membranes. Other surfaces within the oxygenator contacting the blood flow likewise receive the coating.